Minerva Neurosciences, Inc. financial data

Symbol
NERV on Nasdaq
Industry
Pharmaceutical Preparations
Location
1601 Trapelo Road, Suite 286, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.15K % -47.4%
Debt-to-equity -267 % +36.1%
Return On Equity 104 % -28.9%
Return On Assets -62.1 % -35.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.99M shares 0%
Common Stock, Shares, Outstanding 6.99M shares 0%
Entity Public Float 36.9M USD +116%
Common Stock, Value, Issued 699 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.57M shares +37.3%
Weighted Average Number of Shares Outstanding, Diluted 7.57M shares +37.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.2M USD +60.3%
General and Administrative Expense 10M USD -0.28%
Operating Income (Loss) -26.2M USD -30.1%
Net Income (Loss) Attributable to Parent -33.6M USD -25.6%
Earnings Per Share, Basic -4.4 USD/shares +11.6%
Earnings Per Share, Diluted -4.4 USD/shares +11.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.9M USD -40.4%
Assets, Current 31.4M USD -39.9%
Property, Plant and Equipment, Net 8.16K USD -40%
Goodwill 14.9M USD 0%
Assets 46.3M USD -31.1%
Accounts Payable, Current 828K USD +178%
Liabilities, Current 4.2M USD +120%
Liabilities 90.8M USD +14%
Retained Earnings (Accumulated Deficit) -414M USD -8.86%
Stockholders' Equity Attributable to Parent -44.5M USD -256%
Liabilities and Equity 46.3M USD -31.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.09M USD -5181%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 6.99M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.09M USD -5181%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31M USD -40.3%
Deferred Tax Assets, Valuation Allowance 96.9M USD +7.5%
Deferred Tax Assets, Gross 96.9M USD +7.5%
Deferred Tax Assets, Operating Loss Carryforwards 34.5M USD +29.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 431 USD -51.6%
Share-based Payment Arrangement, Expense 1.75M USD -41%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%